April 20, 2021
Cellphire Therapeutics Names Michael Gaffney as Company’s New CEO
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that Michael Gaffney has joined the company as Chief Executive Officer, effective immediately. Mr. Gaffney brings deep health sector insight, extensive operational experience, and proven strategy and capital markets expertise to Cellphire. He will also join the Company’s board.
April 5, 2021
Cellphire, Inc. Announces Rebrand to Cellphire Therapeutics, Inc.
Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today the company’s rebranding to Cellphire Therapeutics, Inc. The significant rebrand includes a new logo and website.
April 2, 2021
Cellphire Therapeutics Closes $15 Million Series A Funding Round Led by Simcah Management
Cellphire Therapeutics, Inc., the global leader in long-term stabilization and storage of platelets, announced today the close of a $15 million Series A financing round led by Simcah Management.
September 23, 2020
Cellphire President G. Michael Fitzpatrick Awarded Armed Services Program Lifetime Achievement Award
Cellphire, the global leader in long-term stabilization and storage of platelets, is proud to announce that the Armed Services Blood Program (ASBP) has awarded Cellphire President G. Michael Fitzpatrick, PhD, with the 2020 ASBP Lifetime Achievement Award for his service and significant contributions to ASBP and the warfighter.
June 3, 2020
Cellphire Subsidiary, BodeVet, Inc., Awarded $1.7 Million U.S. Army Contract
BodeVet, Inc., a Maryland-based company focused on the development of novel blood products for use in veterinary transfusion, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the company a 2-year contract valued at $1.7 million to conduct a clinical trial in canine polytrauma patients at veterinary critical care hospitals.
May 18, 2020
Cellphire Begins Phase 2 Trial of Thrombosomes® in Bleeding Thrombocytopenic Patients
Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to start a Phase 2 clinical trial of Thrombosomes in bleeding patients with thrombocytopenia.
May 14, 2020
Cellphire Announces Orphan Drug Designation of Thrombosomes® for Treatment of Acute Radiation Syndrome
Cellphire, the global leader in long-term stabilization and storage of platelets, announced today that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for its platelet-based freeze-dried hemostatic, Thrombosomes®, for treatment of acute radiation syndrome (ARS).
April 21, 2020
Cellphire Announces Exercise by BARDA of Option 3 of Contract to Develop Platelet-Based Hemostatic
Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised its third contract option valued at $33.3 million to support Cellphire’s next generation platelet-based hemostatic product, Thrombosomes®, through a Phase 2 clinical trial in bleeding thrombocytopenic patients.